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Background: Aging is considered an important independent risk factor for atherosclerosis. Down syndrome people
(DS) display an accelerated aging process compared to healthy subjects, anyway they are relatively resistant to
developing atherosclerosis. The mechanisms involved in such protective effect are not well known. Since heart-type
fatty acid binding protein (H-FABP) is a protein involved in the transport of fatty acids and it has been recently
correlated with the presence of atherosclerosis, we aimed to measure H-FABP level both in DS and in healthy
subjects during aging to evaluate the association between this molecule, aging and atherosclerosis.
Findings: We quantified plasmatic H-FABP level in three groups of male DS and age-matched healthy subjects
(children, age 2–14 years; adults, age 20–50 years; elderly, > 60 years) using a biochip array analyzer. We observed
that aging is associated with increased H-FABP level in healthy subjects but not in DS which display both the same
protein level in the different ages of life and have also lower level compared to their age-matched healthy subjects.
Conclusion: Reduced H-FABP level during aging in DS may play a protective role against atherosclerosis. The
potential involvement of H-FABP in the relationship between aging, atherosclerosis and development of coronary
artery disease needs further investigations.
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Atherosclerosis is a chronic inflammatory response of
the walls of arteries mainly due to a deregulated lipid
metabolism and promoted by the local accumulation of
macrophages [1]. In addition to the well known risk fac-
tors, including hypertension, diabetes, low-density lipo-
protein cholesterol and smoking, increasing evidence
suggested that aging is also an important independent
risk factor for atherosclerosis, persisting also when other
known factors are controlled [2].
Heart-type fatty acid binding protein (H-FABP) is a
small intracellular protein involved in the transport of
hydrophobic long-chain fatty acids from the cell mem-
brane inside the cells. In addition, it also promotes the
expression of different pro-inflammatory cytokines and
is a powerful regulator of the mitochondrial beta-* Correspondence: elena.vianello@unimi.it
1Dipartimento di Scienze Biomediche per la Salute, Cattedra di Patologia
Clinica, Università degli Studi di Milano, Via Mangiagalli 31, Milan 20133, Italy
Full list of author information is available at the end of the article
© 2013 Vianello et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the oroxidative system in the heart [3,4]. A recent study indi-
cated that circulating H-FABP is positive correlated with
intima-media thickness and may represent a new pos-
sible diagnostic biomarker for early atherosclerosis [5].
Several studies shown that people affected by down
syndrome (DS) are relatively resistant to developing ath-
erosclerosis and coronary artery diseases despite the
presence of an unfavourable plasma lipid profile and are
generally considered an “atheroma-free” model [6-8].
For these reasons, due to the absence of atheroscler-
osis in DS, in the present study we aimed to measure
H-FABP level both in DS and in healthy subjects during




Three groups of male DS and age-matched healthy sub-
jects were studied: the first consisted of 23 DS and 20
healthy children (age 2–14 years); the second of 14 DSl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 2 H-FABP level in down syndrome people (DS) and
healthy subjects (CTR) classified according to age. DS and in
CTR were subdivided in three groups according to age: the first
included children (age 2–14 years); the second adults (age 20–
50 years); the third elderly ( > 60 years). H-FABP was measured in
each group and comparison has been performed both between DS
and age-matched CTR and between the three DS and CTR age
groups. *p < 0.001 vs. age-matched CTR, °p < 0.01 vs. adults CTR,
°° p < 0.001 vs. children CTR.
Vianello et al. Immunity & Ageing 2013, 10:2 Page 2 of 3
http://www.immunityageing.com/content/10/1/2and 20 healthy adults (age 20–50 years); the third group
of 13 DS and 20 healthy elderly (> 60 years). All DS were
assessed by clinical examination and karyotype analysis;
they had mild and variable degree of mental retardation,
no other pathological conditions at the time of the study
and were in good health. The project was approved by
University of Milan Ethics Committee and by the
Fondazione Antoniana of Bologna, Italy.
FABP assay
Plasma was obtained by centrifugation at 1500 g for
15 min, transferred into coded plastic tubes, rapidly fro-
zen and stored at −20°C until analysis. H-FABP was
quantified using a biochip array analyzer (Evidence Inva-
tigator, Randox Ltd., Crumlin, UK). A biochip is a solid
substrate supporting an array of discrete test regions,
with immobilized antigen-specific antibodies. After an
immuno-enzymatic reaction, each spot generates a
chemiluminescent signal on the array which is captured
by a charge-coupled camera (CCD-camera) and con-
verted by an image processing software to provide
results comparable with calibration curves.
Statistical analysis
The results are given as mean ± standard deviation (SD).
Comparison between groups was performed using Stu-
dent’s two-tailed t test. A p value < 0.05 was considered
significant. Analyses were performed using GraphPad
Software (San Diego, CA).
Results
By comparing DS and healthy subjects groups (age range
2–65 years) we observed lower H-FABP level in DS
group (1.13 ± 0.34 ng/mL vs. 3.49 ± 0.96 ng/mL;
p < 0.0001) (Figure 1).
Figure 2 shows that H-FABP level is statistically sig-
nificantly lower in DS than in age-matched healty*
Figure 1 H-FABP level in down syndrome people (DS)
compared to healthy subjects (CTR). H-FABP level was evaluated
in DS and in CTR groups (age range 2–65 years). *p < 0.0001 vs. CTR.subjects (DS children 1.14 ± 0.41 ng/ml vs. healthy
children 2.71 ± 0.51 ng/ml, p < 0.001; DS adults 1.11 ±
0.29 ng/ml vs. healthy adults 4.11 ± 0.35 ng/ml,
p < 0.001; DS elderly 1.18 ± 0.23 ng/ml vs. healthy elderly
5.1 ± 0.15 ng/ml, p < 0.001).
Healthy subjects displayed a trend of increase in
H-FABP level with aging (children vs. adults p < 0.001;
elderly vs. adults p < 0.01). On the contrary, no differ-
ence has been observed in H-FABP level between
children, adults and elderly DS (Figure 2).
Discussion
The main finding of our study is that aging is normally
associated with increased H-FABP level but this is not
true in DS which display not only the same level in the
different ages of life but have also lower level compared
to their age-matched healthy subjects. Our study is in
agreement with previous observation which described a
striking increase in H-FABP value with aging [9] and, to
our knowledge, is also the first comparing circulating
H-FABP level in DS and healthy subjects.
The unchanged H-FABP level during aging in DS and
the lack of atherosclerosis in these subjects prompted us
to consider H-FABP as one potential molecule linking
aging and atherosclerosis.
It is well know that aging is associated with reduced
cellular proliferative potential, increased propensity to
undergo death, elevated DNA damage and, at vascular
level, increased expression of pro-inflammatory and
leukocyte adhesion molecules and increased uptake of
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mote atherosclerosis [2]. Although the same mechan-
isms are present in DS, which also display an accelerated
aging process compared to healthy subjects, anyway they
resulted protected against atherosclerosis [10,11]. The
mechanisms that may be involved in such protective
effect are not well known. Anyway, our observation
highlighted that reduced H-FABP level may contribute
to this general protection.
Our study have some limitations, including the
reduced sample size, the lack of correlation with biocli-
nical parameters and atherosclerosis-related risk factors.
For these reasons, our data may be considered prelimin-
ary observations which need further investigation to
better understand the relationship between H-FABP,
atherosclerosis and coronary artery disease.
In conclusion, reduced H-FABP level during aging in DS
may play a protective role against atherosclerosis. This
observation highlighted a potential involvement of H-FABP
in the relationship between aging and atherosclerosis.
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